Bafilomycin C1

Bafilomycin C1 is a macrolide antibiotic isolated from Streptomyces sp. Bafilomycin C1 is a potent, specific and reversible inhibitor of vacuolar-type H+-ATPases (V-ATPases). Bafilomycin C1 inhibits growth of gram-positive bacteria and fungi. Bafilomycin C1 induces cell apoptosis and can be used for the study of hepatocellular carcinoma (HCC).

Product information

CAS Number: 88979-61-7

Molecular Weight: 720.89

Formula: C39H60O12

Chemical Name: (2E)-4-{[(2R, 4R, 5S, 6R)-2-hydroxy-2-[(2S, 3R, 4S)-3-hydroxy-4-[(2R, 3S, 9S, 10S, 11R)-10-hydroxy-3, 15-dimethoxy-7, 9, 11, 13-tetramethyl-16-oxo-1-oxacyclohexadeca-4, 6, 12, 14-tetraen-2-yl]pentan-2-yl]-5-methyl-6-(propan-2-yl)oxan-4-yl]oxy}-4-oxobut-2-enoic acid

Smiles: CC(C)[C@H]1O[C@](O)(C[C@@H](OC(=O)/C=C/C(O)=O)[C@@H]1C)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)C(=CC(C)=C[C@@H](C)[C@@H](O)[C@@H](C)CC(C)=CC=C[C@@H]1OC)OC |t:30,33,43,45|

InChiKey: WUDBXVQNMOTFEE-MRMZCBELSA-N

InChi: InChI=1S/C39H60O12/c1-21(2)36-26(7)31(49-33(42)16-15-32(40)41)20-39(46,51-36)28(9)35(44)27(8)37-29(47-10)14-12-13-22(3)17-24(5)34(43)25(6)18-23(4)19-30(48-11)38(45)50-37/h12-16,18-19,21,24-29,31,34-37,43-44,46H,17,20H2,1-11H3,(H,40,41)/b14-12-,16-15+,22-13-,23-18-,30-19+/t24-,25+,26-,27-,28-,29-,31+,34-,35+,36+,37+,39+/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Bafilomycin C1 (0.33-10 μM; 6 days) inhibits the growth and proliferation of SMMC7721 and HepG2 cells in a timeand dose-dependent manner. Bafilomycin C1 (0.33-3.3 μM; 24 hours) decreases cyclin D3, cyclin E1, CDK2, CDK4, and CDK6 expression in both mRNA and protein expression in SMMC7721 cells. Bafilomycin C1 (3.3-10 μM; 24 hours) causes morphological alterations and increases the population of apoptotic cells by Hoechst 33258 (HY-15558) staining compared to vehicle.

In Vivo:

Bafilomycin C1 (subcutaneous injection; 0.2 mg/kg; 20 days) retards the tumor growth without apparent adverse reactions or side effects in nude mice model.

References:

1. E J Bowman, et al. Bafilomycins: A Class of Inhibitors of Membrane ATPases From Microorganisms, Animal Cells, and Plant Cells. Proc Natl Acad Sci U S A. 1988 Nov;85(21):7972-6.
2. Xiaoxiao Gao,et al.Bafilomycin C1 Induces G0/G1 Cell-Cycle Arrest and Mitochondrial-Mediated Apoptosis in Human Hepatocellular Cancer SMMC7721 Cells. J Antibiot (Tokyo). 2018 Sep;71(9):808-817.

Products are for research use only. Not for human use.